ELX-02 disulfate NB-124 disulfate|cas:2244622-33-9|西域试剂

ELX-02 disulfate NB-124 disulfate,98.0%

产品编号：Bellancom-114231B| CAS NO：2244622-33-9| 分子式：C₁₉H₄₂N₄O₁₈S₂| 分子量：678.68

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-114231B	￥5500.00	杭州北京（现货）
Bellancom-114231B	￥9800.00	杭州北京（现货）
Bellancom-114231B	￥15000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

ELX-02 disulfate NB-124 disulfate

产品介绍

ELX-02 disulfate (NB-124 disulfate) 是一种首创的的合成的真核核糖体特异性糖苷 (ERSG)，可用于研究无义突变引起的遗传疾病。

生物活性

ELX-02 disulfate (NB-124 disulfate) is an investigational, advanced synthetic eukaryotic ribosome selective glycoside (ERSG). ELX-02 disulfate is being developed as a therapy for genetic diseases caused by nonsense mutations.

体外研究

ELX-02 (100-400 μg/mL) is not toxic, and permits read-through of nonsense mutations in human cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay

Cell Line:	Wildtype human proximal tubule cells (HK-2)
Concentration:	0, 100 and 400 μg/mL
Incubation Time:	0, 24, 48 and 72 hours
Result:	Cytotoxicity assay in wildtype human proximal tubule cells (HK-2) showing no toxic effect of 400 μg/mL at 0, 24, 48 and 72 h.

体内研究
(In Vivo)

ELX-02 (10 and 30 mg/kg; repeat subcutaneous administration; twice weekly, total of 8 doses) shows accumulation in tissues that is dose dependent without gender difference.
In plasma ELX-02 is rapidly absorbed with a T_max of 0.25 h after both single (a single subcutaneous injection at 10 mg/kg at dose volume of 5 mL/kg) and repeated administration (twice weekly with 10 mg/kg/dose for 21 days; total of 7 administrations). ELX-02 is rapidly eliminated from plasma in a biphasic manner with the terminal half-life (T_1/2) of 0.5 h.
In a Ctns^Y226X nonsense mutant mouse, subcutaneous ELX-02 accumulates in kidney tissue without overt renal toxicity and that ELX-02 (10 mg/kg X2/week for 3 weeks) reduces renal cystine accumulation in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Twenty-nine Ctns^Y226X/Y226X mice 5-7 month old
Dosage:	10 and 30 mg/kg
Administration:	Subcutaneous injection, at dose volume of 5 mL/kg, twice weekly for a period of 28 days (total of 8 doses)
Result:	Highest levels were measured in the kidney, followed by spleen and liver, with lower levels in other tissues (lung, heart, cochlea and brain).

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Twenty-nine Ctns^Y226X/Y226X mice 5-7 month old
Dosage:	10 and 30 mg/kg
Administration:	Subcutaneous injection, at dose volume of 5 mL/kg, twice weekly for a period of 28 days (total of 8 doses)
Result:	Highest levels were measured in the kidney, followed by spleen and liver, with lower levels in other tissues (lung, heart, cochlea and brain).

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Twenty-nine Ctns^Y226X/Y226X mice 5-7 month old
Dosage:	10 and 30 mg/kg
Administration:	Subcutaneous injection, at dose volume of 5 mL/kg, twice weekly for a period of 28 days (total of 8 doses)
Result:	Highest levels were measured in the kidney, followed by spleen and liver, with lower levels in other tissues (lung, heart, cochlea and brain).

性状

Solid

溶解性数据

In Vitro:

H₂O : 100 mg/mL (147.34 mM; Need ultrasonic)

DMSO : < 1 mg/mL (insoluble or slightly soluble)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.4734 mL	7.3672 mL	14.7345 mL
5 mM	0.2947 mL	1.4734 mL	2.9469 mL
10 mM	0.1473 mL	0.7367 mL	1.4734 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (stored under nitrogen)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶